Clinical Trials in Spain / NCT05911750
Recruiting
Observational
Prevalence and Clinical Implications of HPV Infection in Male IBD Patients
NCT05911750 · tracked via the Priya Life Science Spain tracker
Condition(s) studied
HPV InfectionDysplasia AnusOral Cavity Disease
Investigational drug(s) / intervention(s)
Anal pap smear and oral swab for cytology and HPV testing
Anal pap smear and oral swab for cytology and HPV testing: Anal and oral swab sampling for HPV detection (polymerase chain reaction) and cytology
Study summary
The study aims at describing the prevalence of Human Papillomavirus (HPV) infection in anal and oral samples of men with Inflammatory Bowel Disease (IBD) and detecting risk factors for the infection.
Eligibility
Inclusion Criteria:
* Diagnosed Crohn's disease or ulcerative colitis (at least 3 months before enrollment)
* Male
* Age from 18 to 79 years
Exclusion Criteria:
* Unclassified Inflammatory Bowel Disease
* Diarrhea (\> 3 bowel movements/day) with rectal bleeding at enrollment
* Prior full proctectomy
* Inability to collect the biological samples
* Inability to complete the questionnaire
* Refusal to sign the informed consent
Primary outcome measure(s)
- Prevalence (number/percentage) of HPV infection in oral and anal samples — Up to 12 months
PCR analysis will identify the presence of HPV in oral or anal mucosal cells and characterize the genotype of HPV. - Prevalence (number/percentage) of abnormal HPV-related cytology in oral and anal samples — Up to 12 months
Cytology changes will be reported according to the Bethesda classification.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Barcelona | Spain | Recruiting |
More Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau trials in Spain
Deep Brain Stimulation Recovery in Treatment-Resistant Schizophrenia
Active, not recruiting
Triple-A Barcelona Study
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05911750 on ClinicalTrials.gov ↗ ← All trials in Spain